Contingent Value Rights (CVRs) in M&A: Valuation, Disclosure, and Precedent Analysis

A deal announced at “$45 per share in cash” can carry a hidden additional layer of economic value: a contingent value right that will pay shareholders another $8 per share — but only if a drug candidate wins regulatory approval by a defined deadline. Whether that $8 contingency belongs in your precedent record, and at what value, determines whether you are comparing like with like across a deal set that mixes CVR and non-CVR transactions.

Contingent value rights appear most frequently in pharmaceutical and biotechnology acquisitions, where the target holds pipeline assets whose commercial outcome is genuinely uncertain at signing. They occasionally appear in other sectors where a specific pending event (litigation, a contract award, a regulatory decision) creates a material valuation gap between buyer and seller. In all cases, the CVR bridges that gap: the acquirer pays a base price today and grants sellers additional upside if the uncertain event occurs.

This article explains what a CVR is, where its terms are publicly disclosed, how to determine the right value to use in a precedent analysis, and how to document it so your precedent set remains internally consistent.

What a CVR represents

A contingent value right is a non-transferable or transferable right granted to former shareholders of the acquired company. The right entitles its holder to a cash payment — the CVR payout — if and when a specific future event occurs within a defined period. If the event does not occur by the specified deadline, the CVR expires worthless.

Unlike an earnout, which is a private arrangement between the buyer and the selling shareholders or management team and typically depends on the post-closing operating performance of the combined business, a CVR is often granted to former public shareholders at the time of the deal close. In transactions that involve a public target, a CVR may be registered as a security with the SEC and subsequently listed for trading on an exchange, giving it a publicly observable market price.

Three types of events drive most CVR structures:

Regulatory milestone. The CVR pays if a drug, device, or other product receives regulatory approval (typically from the FDA, EMA, or an equivalent authority) by a stated date. The specific approval path — NDA, BLA, PMA, or equivalent — and the deadline are defined in the CVR agreement. Multiple milestones may each have a separate payment component, so that a CVR with a $9 face value might pay $3 for drug A, $3 for drug B, and $3 for drug C, each with its own approval deadline.

Revenue or commercial milestone. The CVR pays if net sales of a specified product (or the combined business) exceed a defined revenue threshold by a stated date or during a specified period. This structure is more common where approval is likely but commercial uptake is uncertain.

Litigation or contingent-liability outcome. The CVR pays if an outstanding legal dispute resolves in a way that generates a material payment to the former entity (for example, a patent-infringement judgment, a government investigation settlement, or recovery under an insurance policy). The CVR effectively passes that uncertain recovery to former shareholders rather than letting the acquirer capture it entirely.

A single CVR agreement may combine more than one trigger type, or may tier a single event into multiple payment levels depending on the magnitude of the outcome.

Where CVR terms are publicly disclosed

For any acquisition of a US-listed public company that includes a CVR, the primary disclosure source is the filed transaction documents. Four filing types are most relevant:

Merger agreement (Exhibit 2.1 to Form 8-K). The acquirer files the merger agreement as an exhibit within four business days of signing. CVR terms are either incorporated in the merger agreement directly or attached as a separate schedule or exhibit. In many transactions, the CVR agreement itself is attached as an exhibit to the merger agreement (commonly Exhibit A or a numbered exhibit). The merger agreement will state the maximum CVR payout per share and reference the CVR agreement for detailed milestone terms.

CVR agreement (Exhibit to merger agreement, or filed separately). The CVR agreement is the operative document. It states the precise event definition, the measurement method, the deadline by which the event must occur, the per-share payment amount, the calculation agent, dispute-resolution procedures, and conditions to payment. Search the Form 8-K filing index for the complete exhibit list to locate this document on EDGAR’s full-text search.

Registration statement (Form S-4 or S-4/A). When the CVR is a registered security, the acquirer files a registration statement covering both the acquirer’s shares and the CVRs issued in the transaction. The registration statement summarizes CVR terms and risk factors in detail. The final prospectus, included in the S-4, is the investor-facing document. EDGAR full-text search will find S-4 filings containing the phrase “contingent value right.”

Proxy statement or combined proxy-prospectus (DEF 14A or S-4). The target’s proxy statement describes CVR terms in the merger consideration section and in the background of the merger narrative. A combined proxy-prospectus (when the acquirer’s shareholders also vote) covers the CVR in both the consideration summary and the risk factors. This is often the most readable plain-language summary of the CVR structure.

For UK schemes of arrangement and other non-US transaction structures, equivalent terms appear in the scheme document or offer document filed with the UK Takeover Panel or the relevant national authority, and in any Securities Act registration statement filed for CVRs or loan notes issued to US holders.

How to value a CVR for a precedent analysis

The core principle is the same as for any other component of consideration: use the announcement-date implied value and apply a consistent reference date across all components of the deal and across all deals in your set.

If the CVR is publicly traded. When the CVR is registered and listed on an exchange, use the exchange market price at your chosen reference date (typically the unaffected date or the announcement date). A publicly listed CVR aggregates the market’s collective view of the probability and timing of the milestone event. Record the exchange, the ticker symbol, the reference date, and the closing price. Do not substitute your own probability estimate when an observable market price exists unless you have reason to believe the market was thin or distorted.

If the CVR is not publicly traded. When the CVR is a private arrangement (which is more common in acquisitions of private targets), use a probability-adjusted expected value:

Expected CVR value = probability of event occurring × maximum CVR payout

The probability estimate should reflect publicly available evidence at the announcement date — clinical trial results, regulatory authority guidance letters, FDA advisory committee outcomes, revenue run-rate relative to milestone thresholds, or, for litigation CVRs, court filings and expert legal commentary. The estimate must be supportable from public sources and stated explicitly in your workpapers.

Worked hypothetical. Acquirer X announces the acquisition of Target Y at $45 cash per share. Each Target share also receives one CVR that pays $8 if Target’s lead drug candidate receives FDA approval by 31 December of Year T+1. The CVR is not publicly traded. Based on Phase 3 trial results and the FDA’s complete response to a prior NDA, you estimate a 55 percent probability of approval.

Expected CVR value = 55% × $8.00 = $4.40 per share

Total consideration per share at announcement: $45.00 + $4.40 = $49.40. That $49.40 (not $45.00 and not $53.00) is the figure you record as equity value per share in your precedent analysis.

What to avoid. Two errors are particularly common. The first is recording only the cash component and ignoring the CVR entirely, on the reasoning that it may never pay. This understates the announced consideration and is incorrect under both IFRS 3 and ASC 805, which require contingent consideration to be measured at fair value on the acquisition date and included in the purchase price. The second error is using the maximum face value rather than an expected value, on the reasoning that the maximum is the stated deal price. This overstates the consideration when the probability of the event is below 100 percent — which is definitional for a contingent right.

Does the CVR belong in enterprise value?

Yes, with the important qualification that you use the announcement-date probability-adjusted value or market price, not the face value.

The CVR represents consideration paid to acquire the target’s equity. It is part of the equity value of the target as defined by the acquirer’s announced willingness to pay. Excluding it understates equity value and therefore understates the EV/EBITDA or EV/revenue multiple (since adding net debt to understated equity value gives an understated EV numerator).

The EV bridge remains unchanged: equity value plus net debt (and other adjustments for leases, pensions, non-controlling interests and similar items) equals enterprise value. If you have included the expected CVR value in equity value, that value flows through to EV. You do not need to treat the CVR separately at the EV level — it is part of the equity value you apply to the bridge.

One practical question arises for pending deals in which the outcome of the CVR event is already known by the time you are conducting your precedent analysis. For consistency, use the announcement-date value. The purpose of a precedent analysis is to understand what the market was pricing the target at the moment of transaction. Restating with the known outcome would introduce hindsight and make comparisons with other deals in your set inconsistent.

CVRs versus earnouts: key distinctions

CVRs and earnouts are both forms of contingent consideration, but they differ in structure, disclosure, and the way they should be treated in a precedent set.

Dimension	CVR	Earnout
Who holds the right	Former shareholders of the target	Sellers or management post-close
Transaction type	Most common in acquisitions of public companies	Most common in acquisitions of private targets
Is it a registered security?	Often yes (filed with SEC, may trade on exchange)	No
Trigger type	Specific binary or milestone events (regulatory approval, revenue threshold, litigation outcome)	Post-close business performance (revenue, EBITDA, unit sales)
Where terms are found	CVR agreement, S-4, proxy statement, Form 8-K exhibits	Merger agreement provisions; no separate public exhibit in private deals
Market-observable value?	Yes, if listed on exchange	No
Maximum payout period	Fixed deadline; expires worthless if not met	Typically one to three years post-close

From a precedent analysis standpoint, earnouts raise similar valuation questions and are covered in the article on how cash, debt, and earnouts affect transaction value. The documentation and probability-adjustment principles are the same; the practical difference is that for public-company CVRs you may have an exchange-listed market price that makes the expected-value calculation unnecessary.

Both CVRs and rollover equity (discussed in the article on rollover equity in M&A transactions) represent forms of consideration that are frequently omitted from headline “cash” figures. CVRs are contingent on a future event; rolled shares are certain in value at closing but not immediately liquid. Both omissions lead to understated multiples if uncorrected.

Consistency across a mixed precedent set

In a sector such as pharmaceuticals, biotechnology, or medical devices, a material proportion of comparable transactions may include CVRs. If you exclude CVR value from some records and include it in others, your enterprise value numerator will be inconsistently defined, and the spread in your multiple range will partly reflect methodology rather than genuine market variation.

The recommended approach:

Identify all CVR deals in the set (search the EDGAR full-text index for “contingent value right” in the filing period for each deal, or check the merger agreement exhibit list for a CVR agreement).
Value each CVR using the announcement-date market price (if traded) or a probability-adjusted expected value (if not traded).
Record the maximum payout, your probability estimate or market price, and the expected CVR value separately in your workpapers.
Include the expected CVR value in the equity value for all CVR deals.
Flag any deal where the CVR payout has since been resolved (paid, partially paid, or expired worthless) with a note that your precedent record uses the announcement-date expected value for comparability.

If a CVR is immaterial (for example, a maximum payout of less than one percent of the deal’s equity value), you may note it and exclude it in the interest of proportionality, but the exclusion should be documented and applied consistently.

Common errors in precedent sets

Treating the headline figure as total consideration. Press releases announcing pharma deals frequently state “total consideration of $X” inclusive of the CVR at face value, or they may state “$X cash consideration” and mention the CVR separately. Neither convention tells you what to record: the first overstates the true expected value by treating the CVR as certain; the second understates it by omitting the CVR entirely. Work from the deal documents, not the press release summary.

Using the CVR payout outcome to restate announcement-date records. Once a deal has closed and the CVR has expired worthless or paid in full, it is tempting to restate the precedent record to reflect the actual payout rather than the expected value. Avoid this. Your precedent set should reflect what the market was pricing at the decision point, not the benefit of hindsight.

Inconsistent reference dates. If you value the cash component at the announcement date, the stock component using the acquirer’s share price at announcement, and the CVR at a traded market price from a week later, you have three different reference points in the same deal record. Apply a single reference date for all components and document it.

Ignoring CVR milestones in the EBITDA denominator selection. If a drug approved under a CVR milestone would have been generating revenue and EBITDA in the period covered by your LTM denominator, the financial period selection question becomes particularly important. Use the LTM financials as of the period defined in the proxy statement and exclude any pro-forma adjustment for post-approval revenue unless the adjustment is explicitly disclosed. For guidance on selecting the financial period, see the article on LTM versus NTM multiples in precedent analysis.

Per-transaction documentation checklist

For each deal that includes a CVR, record:

Source: Form 8-K filing date and accession number; exhibit number of the CVR agreement.
Maximum payout per share: the stated face value of the CVR if all milestones are met.
Milestone description: precise event (drug name, regulatory pathway, revenue threshold, or litigation description) as defined in the CVR agreement.
Milestone deadline: date by which the event must occur for the CVR to pay.
Whether publicly traded: exchange and ticker symbol, if any.
Reference date: the date at which you measured the CVR value.
CVR value used: market price at reference date (if traded) or probability estimate × maximum payout (if untraded), with the probability estimate stated explicitly.
Expected CVR value included in equity value: confirm that this figure is in your equity value numerator.
CVR outcome (known deals): for deals where the CVR has since been resolved, note the actual payout for reference, with a note that the precedent record retains the announcement-date expected value.

Pharma and biotech M&A in particular generates a substantial record of publicly disclosed CVR structures across FDA approval timelines, clinical development stages, and commercial launch scenarios. The terms are uniformly available in SEC filings, making CVR treatment a resolvable documentation problem rather than a reason to exclude a deal from your set.

Access sourced precedent transaction records — including deal structure details, disclosed consideration components, and financial period context — through the searchable database at app.privylogic.ai/pricing. Enterprise teams with bespoke coverage needs can contact the team at contact.

Sources

Merger Agreements Filed as Exhibit 2.1 to Form 8-K — EDGAR Full-Text Search — U.S. Securities and Exchange Commission EDGAR; accessed September 15, 2026
IFRS 3 Business Combinations — Contingent Consideration — IFRS Foundation; accessed September 15, 2026